Krystal Biotech (NASDAQ:KRYS) Shares Gap Down on Insider Selling

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) shares gapped down prior to trading on Wednesday after an insider sold shares in the company. The stock had previously closed at $119.13, but opened at $115.00. Krystal Biotech shares last traded at $116.24, with a volume of 113,087 shares traded.

Specifically, Director Daniel Janney sold 7,900 shares of the firm’s stock in a transaction that occurred on Wednesday, April 19th. The stock was sold at an average price of $90.32, for a total value of $713,528.00. Following the completion of the sale, the director now owns 224,462 shares of the company’s stock, valued at $20,273,407.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Krystal Biotech news, Director Daniel Janney sold 7,900 shares of the business’s stock in a transaction on Wednesday, April 19th. The stock was sold at an average price of $90.32, for a total value of $713,528.00. Following the sale, the director now directly owns 224,462 shares in the company, valued at $20,273,407.84. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, April 17th. The shares were sold at an average price of $87.65, for a total value of $2,191,250.00. Following the completion of the transaction, the insider now owns 1,649,206 shares of the company’s stock, valued at $144,552,905.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 193,428 shares of company stock valued at $17,965,513. Company insiders own 17.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on KRYS. HC Wainwright lifted their price target on Krystal Biotech from $119.00 to $139.00 in a research note on Monday. Chardan Capital raised their target price on Krystal Biotech from $133.00 to $148.00 in a research note on Monday. Bank of America raised their price objective on Krystal Biotech from $105.00 to $118.00 in a research report on Sunday. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research report on Wednesday, March 22nd. Finally, The Goldman Sachs Group raised Krystal Biotech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $79.00 to $124.00 in a report on Tuesday, February 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $134.00.

Krystal Biotech Stock Down 0.5 %

The company has a 50 day simple moving average of $85.89 and a two-hundred day simple moving average of $80.77. The company has a market capitalization of $3.06 billion, a P/E ratio of -22.45 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last announced its quarterly earnings results on Monday, February 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.01. As a group, research analysts expect that Krystal Biotech, Inc. will post -5.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. State Street Corp boosted its position in Krystal Biotech by 52.3% in the 1st quarter. State Street Corp now owns 1,068,656 shares of the company’s stock valued at $71,108,000 after buying an additional 366,855 shares during the period. Braidwell LP purchased a new stake in shares of Krystal Biotech during the 4th quarter worth $28,365,000. Avoro Capital Advisors LLC lifted its position in shares of Krystal Biotech by 24.1% during the 1st quarter. Avoro Capital Advisors LLC now owns 1,750,000 shares of the company’s stock worth $140,105,000 after purchasing an additional 340,000 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Krystal Biotech by 1,010.1% during the 3rd quarter. Victory Capital Management Inc. now owns 303,599 shares of the company’s stock worth $21,161,000 after purchasing an additional 276,251 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Krystal Biotech by 74.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 262,463 shares of the company’s stock worth $17,465,000 after purchasing an additional 111,822 shares during the last quarter. 80.80% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.